" class="no-js "lang="en-US"> Epro - Medtech Alert
Tuesday, September 16, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Epro | Pharmtech Focus

Epro

About Epro

Epro
Epro works with NHS organisations to deploy a modular EPR that improves patient care by integrating NHS hospital systems. Based on a clinically-led approach, Epro supports the rapid deployment of discharge summaries (to the latest standards), handover lists, paperlight clinics, outcoming and many other modules, while also managing patient records and providing powerful reporting capabilities. More information: www.epro.com

Related Story

Diseases

 Liverpool Heart and Chest Hospital Selects Clinical Informatics Provider Epro as Digital Partner | Pharmtech Focus

Liverpool Heart and Chest Hospital Selects Clinical Informatics Provider Epro as Digital Partner

September 29 2022

Leading healthcare informatics provider Epro has been selected by the Liverpool Heart and Chest Hospital (LHCH) to […]